Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
about
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsRole of the Drug Transporter ABCC3 in Breast Cancer ChemoresistanceHelicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis.Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placentaHistone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.Nuclear localization signal domain of HDAC3 is necessary and sufficient for the expression regulation of MDR1.Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.Molecular pathways: regulation and therapeutic implications of multidrug resistancemiR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.The challenge of exploiting ABCG2 in the clinic.Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.ABCG2: a perspective.Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIdentification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant Phenotype.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationHistone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer DrugsRegulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunitiesMicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotypeChemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistanceSynergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).ABCG2: the key to chemoresistance in cancer stem cells?Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues.Epigenetics in cancer stem cells.Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Cancer stem cell epigenetics and chemoresistance.Modulation of gene expression in ovarian cancer by active and repressive histone marks.Human ABCG2: structure, function, and its role in multidrug resistance.The epigenetics of renal cell tumors: from biology to biomarkers.Epigenetic alterations involved in cancer stem cell reprogramming.HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review)hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.
P2860
Q26865927-02EF08C7-BB30-43D6-9DEC-45AAE4991EE5Q27015931-1792CE98-3E18-4A16-A015-016F3DBE0E18Q28552011-2B34FEEB-AB3F-41A2-9BEC-42C6CD474608Q30436545-DECF2D68-202B-4F43-A012-4ECB9D77552AQ31133417-FCFFEAA5-5802-4C2A-85C9-C56550B07F50Q34179757-B5BACDBD-C9E1-4E07-A32F-ED75F9FF391FQ34179956-7C460F47-503D-4120-A725-F58B7F9C7AB8Q34181200-6C466CB4-80EF-42C1-9254-1B02AAF8B1F6Q34255292-30A20E06-A47F-497F-BCCD-DC988244F1AFQ34283601-15724549-5194-4B60-A91A-6256998CF4D0Q34968909-ABAEBD7F-6491-474D-9FD1-3BA1E5F40D6AQ34996536-ABBB9CE8-9F1A-42B2-8401-64BED77EC45BQ35016817-C921098E-CB49-4831-9375-6BF19027CB7BQ35096240-C42B1005-8A98-417F-B354-CF30A355C453Q35186322-A60FBF15-A363-4F84-9756-B3810FFFD955Q36063407-0DE6608F-4C50-4F5C-ADE7-DA93546F6D27Q36521908-4B462A16-A172-4450-A0A3-9AC6F4105107Q36608727-8303C540-1771-4332-9FD2-2F82FC778983Q36693836-D5FA6F6F-B14D-4A3C-B7D6-9A3E8701C3D0Q36846027-0EE35618-559A-49C5-A2B4-CE41241F81A1Q36923079-6C5CC93F-BB9D-4AA7-BA0E-8F534482012DQ36960756-67102D04-7FA6-44AB-9628-2BBC74BCF7FBQ37199087-E6679671-9ACE-4376-802A-700D5BD5C9BCQ37462746-2A5A1DDD-176F-488B-A496-40D3868A95F4Q37478653-B80C3DAE-1614-4924-9BDD-0701252D3E9AQ37536938-CBD89B7F-A57C-4A11-A421-0E8C1F0B28F2Q37560771-6094497C-2D96-4134-9C87-CED781AEE013Q37587219-735C2B2B-C530-40D2-9569-8247830D5D08Q37604379-7616EC31-1A20-469E-8FD8-5159F5AFB6F7Q37618640-A853C74A-2425-45E1-88DA-238FAF47DAECQ37630384-54A84D0F-8092-4833-973A-7390511DBBCAQ37853578-92A1C356-8AEF-49BE-B7F4-8666D39D9715Q37958162-7751D4F9-3B7B-4198-B288-6A10805B350BQ37961977-DBAFA862-49AF-4569-AADB-05F4D67EDFEEQ37962015-F62732AF-695C-4797-B225-73CC078A8EDDQ38003156-B5A026A0-928E-4334-9937-D060F4070BAEQ38016153-200F4F92-4464-489B-BA87-8EED8AE0C579Q38058972-AD575F0B-79AE-44D8-A71A-4C0E1D175053Q38333926-59122715-DA61-4D93-83BA-8D2CCF23073BQ38342516-E0238999-084F-4B79-99D5-5B9CFB7F79AF
P2860
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Histone modifications at the A ...... in multidrug-resistant cells.
@ast
Histone modifications at the A ...... in multidrug-resistant cells.
@en
type
label
Histone modifications at the A ...... in multidrug-resistant cells.
@ast
Histone modifications at the A ...... in multidrug-resistant cells.
@en
prefLabel
Histone modifications at the A ...... in multidrug-resistant cells.
@ast
Histone modifications at the A ...... in multidrug-resistant cells.
@en
P2093
P2860
P1476
Histone modifications at the A ...... in multidrug-resistant cells.
@en
P2093
Kenneth K W To
Kuniaki Morisaki
Lyn M Huff
Orsolya Polgar
Susan E Bates
P2860
P304
P356
10.1158/1541-7786.MCR-07-0175
P577
2008-01-01T00:00:00Z